HER2 amplified or overexpressed in approximate 15 - 20% of breast cancer and associated with aggressive clinical feature if absence therapy (Figueroa-Magalhaes et al., 2014; Krishnamurti and Silverman, 2014). Here, ERBB2 is linked to breast cancer.